Thursday saw the publication of a research note by HC Wainwright, which marked the beginning of the firm’s coverage of OPKO Health (NASDAQ: OPK). The investment firm recommended to its customers that they “purchase” shares of the biotechnology company.
StockNews.com initiated coverage of OPKO Health shares with the publication of a story on October 12th, which marked the beginning of their coverage. They recommended “selling” the stock to prospective buyers. The company’s stock has received the opinions of three research analysts, two of whom have recommended an acquisition, one of whom has recommended a hold, and one of whom has recommended a sale. The data from Bloomberg.com indicates that the consensus view regarding OPKO Health’s stock is to “hold” the stock, and the average price objective is $4.00.
OPK shares officially started trading for the first time on Thursday for $1.29 per share. Currently, the company has a P/E ratio of -2.93, a beta value of 1.62, and a market value of $996.76 million. The financial ratios are as follows:
The debt-to-equity ratio is at zero.
The quick ratio is at one.
The current ratio is 1.55.
The current ratio is 0.09.
The company has seen a moving average of $1.64 over the past 50 days, and the moving average for the last 200 days is $2.15. Over the previous twelve months, the price of OPKO Health has fluctuated between $1.28 and $5.25 at various points.
In other news about this topic, on September 19th, Chief Executive Officer Phillip M. et al. Frost purchased 50,000 shares of company stock. This was disclosed in a different report of recent events. The price for each share was $1.97, which resulted in the overall cost of the acquisition being $98,500. The price paid per share on average was $1.97. As a consequence of the acquisition, the Chief Executive Officer now owns 197,506,694 shares. The total value of these shares is $389,088,187.18. The documentation that describes the transaction was submitted to the Securities and Exchange Commission, and it is possible to locate it on the SEC’s website. Company insiders have spent a combined total of $1,975,250 over the past three months to acquire 1,175,000 shares. The current percentage of the company’s stock held directly by company insiders is 40.97%.
In the most recent few months, several well-known shareholders have revised the percentages of ownership in the company they currently hold. To acquire a new position at OPKO Health over the third quarter, Humankind Investments LLC forked over $25,000. Zacks Investment Management made a new investment in the amount of $25,000 in OPKO Health during the third quarter of 2018. Aigen Investment Management LP added $29,000 to the sum of money that it had previously invested in OPKO Health during the second quarter. During the third quarter of 2018, Susquehanna International Group Ltd. invested $35,000 in OPKO Health through a capital contribution. During the second quarter, Verition Fund Management LLC made a new investment in OPKO Health that totaled $36,000. OPKO Health was the recipient of this investment. Institutional and hedge fund investors hold ownership positions equivalent to 27.83% of the total number of shares issued by the company.
Diagnostics and the pharmaceutical industry are two of the many fields that OPKO Health, Inc., a company that provides medical services and operates in multiple countries, including the United States of America, Ireland, Chile, Spain, Israel, and Mexico, works in, respectively. BioReference Laboratories, managed by the company’s Diagnostics division, offers testing services for detecting, diagnosing, evaluating, monitoring, and treating disease. These services can be obtained by contacting BioReference Laboratories. Employers and governmental agencies, medical offices and clinics, hospitals, and private clinics, can take advantage of these services. This category encompasses a wide range of medical specialties, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare, to name just a few.